Kalytera Announces Issuance of Shares under Services Agreement with The Salzman Group of Israel
January 26, 2018 08:00 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that the Company has...
Kalytera Announces Settlement of Debt Transaction
January 11, 2018 22:43 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it has entered into an...
Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel
December 22, 2017 17:29 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that the TSX Venture...
Kalytera Therapeutics, Inc. Announces Closing of Brokered Private Placement
December 20, 2017 17:13 ET
|
Kalytera Therapeutics, Inc.
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANCISCO...
Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team
December 07, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) and (OTCQB:KALTF) (the "Company" or "Kalytera") today announced the initiation of a...
Kalytera Confirms No Material Change in Operations
December 05, 2017 11:10 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, Dec. 05, 2017 (GLOBE NEWSWIRE) -- At the request of IIROC, Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") wishes to confirm...
Kalytera Announces $5 Million Private Placement of Convertible Debenture Units
November 22, 2017 07:45 ET
|
Kalytera Therapeutics, Inc.
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ SAN FRANCISCO and TEL AVIV, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY)...
Kalytera Receives IRB Approval for Proposed Phase 2 Study Evaluating CBD in the Prevention of Graft versus Host Disease
September 07, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO, Calif. and TEL AVIV, Israel, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing...
Kalytera Reports Second Quarter 2017 Financial Results
August 31, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid...
Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease
August 14, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid...